Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine quadrivalent - Seqirus

Next Previous
Search
Drug Profile

Influenza virus vaccine quadrivalent - Seqirus

Alternative Names: Adjuvanted quadrivalent influenza vaccine - Seqirus; Adjuvanted quadrivalent influenza vaccine surface antigen inactivated - Seqirus; Adjuvanted quadrivalent subunit influenza virus vaccine - Seqirus; aIIV-B - Seqirus; aIIV-C - Seqirus; aQII; aQIV - Seqirus; aQIVc - Seqirus; Cell based quadrivalent subunit influenza virus vaccine - Seqirus; FLUAD QUADRIVALENT; Fluad Tetra; IIV-A - Seqirus; MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine; MF59 adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine - Seqirus; MF59-Adjuvanted influenza vaccine - Seqirus; MF59-Adjuvanted quadrivalent subunit inactivated Influenza Vaccine - Seqirus; MF59® - Adjuvanted seasonal influenza vaccine - Seqirus; Subunit inactivated influenza vaccine - Seqirus

Latest Information Update: 26 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Seqirus
  • Class Influenza A virus H1N1 vaccines; Influenza virus vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 30 Jan 2025 Seqirus completes a phase-III clinical trials in Influenza virus infections (Prevention) in the USA, Canada, Denmark, Estonia, Germany, Pakistan, Philippines and United Kingdom (IM) (NCT06015282)
  • 03 Nov 2023 Phase-III clinical trials in Influenza virus infections (Prevention) in Canada (IM) (NCT06015282)
  • 03 Nov 2023 Phase-III clinical trials in Influenza virus infections (Prevention) in Estonia (IM) (NCT06015282)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top